CALCIUM ANTAGONISTS IN ARTERIAL HYPERTENSION TREATMENT: SPECIFICS OF LERCANIDIPINE
https://doi.org/10.15829/1560-4071-2015-2-110-114
Abstract
Lercanidipine is a dihydropyridine calcium antagonist of the 3rd generation, with high level of vasoselectivity, long lasting effect and good antihypertensive effectiveness. The review shows the main specifics of pharmacokinetics and mechanism of action of the drug. It is known that lercanidipine supports renoprotection, left ventricle hypertrophy reduction, improvement of elastic properties of the vessels and central blood pressure decrease. Sympathetic activation in lercanidipine is almost absent, that makes up its good tolerability and improves patients’ compliance.
About the Author
I. O. Minushkina
FSBI Studying-Scientific Medical Centre of the President PA, Moscow
Russian Federation
Russian Federation
References
1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension 2013, 31: 1281-57.
2. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs. 1999 Jul; 8(7): 1043-62.
3. Reddy GS, Nayak UY, Deshpande PB, Mutalik S . Gastroretentive Pulsatile Release Tablets of Lercanidipine HCl: Development, Statistical Optimization, and In Vitro and In Vivo Evaluation. ScientificWorldJournal. 2014; 2014: 421931.
4. Brixius K, Gross T, Tossios P, et al. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue. Clin Exp Pharmacol Physiol. 2005 Sep; 32(9): 708-13.
5. Grassi G, Seravalle G, Turri C, et al. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003 Mar; 41(3): 558-62.
6. Vasigar P, Batmanabane M. Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013 Oct; 4(4): 238-42.
7. Farah R, Khamisy-Farah R, Shurtz-Swirski R. C alcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol. 2013 Feb; 32(1): 85-93.
8. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009 Aug; 54(2): 409-13.
9. Martinez ML, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan; 47(1): 117-22.
10. Poncelet P, Ribstein J, Goullard L, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study Ann Cardiol Angeiol (Paris). 2004 Jun; 53(3):123-30.
11. Wu Y, Xu M, Wang H, et al. Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. Curr Med Res Opin. 2015 Jan; 31(1): 171-6.
12. Thuc Sinh C, Van Minh H, Van Huy T . E ffects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Curr Med Res Opin. 2015 Jan; 31(1): 163-70.
13. Millar-Craig M, Shaffu B, Greenough A, et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens. 2003 Nov; 17(11): 799-806.
14. McClellan KJ, Jarvis B . Lercanidipine: a review of its use in hypertension. Drugs. 2000 Nov; 60(5): 1123-40.
15. Cicero AF, Gerocarni B, Rosticci M, Borghi C . B lood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens. 2012; 34(2): 113-7.
16. Yang Z. E fficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension. Curr Med Res Opin. 2015 Jan; 31(1): 183-6.
17. De Ciuceis C, Salvetti M, Rossini C, et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014 Mar; 32(3): 565-74.
18. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004 Oct; 17(5): 259-266.
19. Peng M, Jiang XJ, Dong H, et al. Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr Med Res Opin. 2015 Jan; 31(1): 177-82.
20. Robles NR, Pastor L, Manjón M, et al. Lercanidipine in diabetic patients with renal failure. Nefrologia. 2004; 24(4): 338-43.
21. Topal C, Erkoc R, Sayarlioglu H, Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients. . Ren Fail. 2009; 31(6): 446-51.
22. Campo C, Saavedra J, Segura J, et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005 Oct; 96(5): 365-71.
23. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009 Aug; 54(2): 409-13.
24. Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Press. 2006; 15(5): 268-74.
25. Tisaire-Sánchez J, Roma J, Camacho-Azcargorta I, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag. 2006; 2(4): 491-87.
26. Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract. 2006 Nov; 60(11): 1364-70.
27. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003 Nov-Dec; 37(3): 203-12.
28. Romito R, Pansini MI, Perticone F, et a. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4): 249-53.
29. Sansanayudh N, Wongwiwatthananukit S, Veerayuthvilai S . C omparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai. 2010 Nov; 93 Suppl 6: S84-92.
30. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003 May; 21(5): 1003-10.
31. Elliott HL, Meredith PA. Thrapeutic equivalence in the treatment of hypertension: Can lercanidipine and nifedipine GITS be considered to be interchangeable? World J Cardiol. 2014 Jun 26; 6(6): 507-13.
32. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P . Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther. 2009 Aug; 31(8): 1652-63.
33. Prandin MG, Cicero AF, Veronesi M, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens. 2007 Nov; 29(8): 553-62.
Review
For citations:
Minushkina I.O. CALCIUM ANTAGONISTS IN ARTERIAL HYPERTENSION TREATMENT: SPECIFICS OF LERCANIDIPINE. Russian Journal of Cardiology. 2015;(2):110-114. (In Russ.) https://doi.org/10.15829/1560-4071-2015-2-110-114
Views:
1331
Email this article 